JNJ-87704916 — Investigational Agent
Other · Phase 1 · Johnson & Johnson
Mechanism of Action
Intratumorally administered engineered oncolytic virus that selectively replicates in and lyses tumor cells while stimulating a local and systemic anti-tumor immune response. Studied as monotherapy and in immunotherapy combinations for advanced solid tumors including lung cancer.
Investigational Indications
- Advanced solid tumors
- Non-small cell lung cancer